lapatinib has been researched along with captopril in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (captopril) | Trials (captopril) | Recent Studies (post-2010) (captopril) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 10,320 | 1,514 | 890 |
| Protein | Taxonomy | lapatinib (IC50) | captopril (IC50) |
|---|---|---|---|
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 3.6 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.084 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.0173 | |
| Succinyl-diaminopimelate desuccinylase | Haemophilus influenzae Rd KW20 | 3.3 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.1004 | |
| Beta-lactamase | Pseudomonas aeruginosa | 5 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.011 | |
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | 3.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
1 review(s) available for lapatinib and captopril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for lapatinib and captopril
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |